{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Review by the Investigator or qualified personnel on the 1572 of laboratory test results.', 'Adverse events (start and stop date, description, action taken, and resolution).', \"Investigator or sub-investigator's signed assessment of each AE.\", 'Concomitant medications (start and stop dates, reason for use).', 'Condition of subject upon completion of, or PW from, the study.', '11 CASE REPORT FORMS', 'An eCRF is required for every subject who signs the ICF. Required data must be entered on the', 'eCRF within the required time period, which will be outlined within each site agreement, after', 'data collection or the availability of test results. Separate source records are required to support', 'all eCRF entries. Data captured on the eCRF, and requested anonymized copies of supporting', 'documents, will be transferred to the Sponsor at study completion.', 'The Investigator will ensure that the eCRFs are accurate, complete, legible, and timely, and will', 'review and provide an electronic signature for the eCRF according to the standard operating', 'procedure of the CRO Data Management System. Final eCRFs will be provided to the', 'Investigator and Sponsor by CRO Data Management.', '12 STUDY MONITORING', 'The Investigator will ensure that the study is conducted in accordance with all regulations', 'governing the protection of human subjects. The Investigator will adhere to the basic principles', 'of GCP as outlined in Title 21 of the CFR, Part 312, Subpart D, \"Responsibilities of Sponsors', 'and Investigators\"; 21 CFR, Part 50, \"Protection of Human Subjects\"; 21 CFR, Part 56,', '\"Institutional Review Boards\"; 21 CFR, Part 54 \"Financial Disclosure by Clinical Investigators\";', 'and the ICH guideline entitled \"Good Clinical Practice: Consolidated Guidance\". Additionally,', 'this study will be conducted in compliance with the Declaration of Helsinki and with all local', 'laws and regulations.', 'The Investigator will ensure that all work and services described in, or associated with, this', 'protocol are conducted in accordance with the investigational plan, applicable regulations, and', 'the highest standards of medical and clinical research practice. The Investigator will provide', 'copies of the study protocol and IB to all Sub-Investigators, pharmacists, and other staff', 'responsible for study conduct.', 'All aspects of the study will be monitored by qualified individuals designated by the Sponsor.', 'The Sponsor will ensure that the study is monitored adequately in accordance with GCP', 'guidelines.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 107 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', \"Prior to initiation of the study, the Sponsor's representatives will review with study center\", 'personnel information regarding the investigational drug, protocol requirements, monitoring', 'requirements, and reporting of SAEs.', 'At intervals during the study, as well as after the completion of subject enrollment, the study', 'center will be monitored by the Sponsor or designee for compliance. During these visits, the', 'masked monitor will discuss study progress, verify adherence to the protocol and the', 'completeness, consistency, and accuracy of the data being entered on the eCRF (source data', 'verification); oversee the resolution of outstanding data discrepancies, and check on various', 'aspects of study conduct (e.g., drug accountability, sample storage). The Investigator agrees', 'to', 'allow unmasked monitors access to the clinical supplies, dispensing and storage areas, and', 'clinical records of the study subjects, and, if requested, agrees to assist the monitors. The', 'Investigator must cooperate with the monitors to ensure that any problems detected in the course', 'of these monitoring visits are resolved.', 'A secondary audit may be conducted by Quality Assurance designated by the Sponsor. The', 'Investigator will be informed if this is to take place and advised as to the nature of the audit.', 'Representatives of the US FDA and/or representatives of other regulatory authorities may also', 'conduct an inspection of the study at the investigative site. If informed of such an inspection, the', 'Investigator should notify the Sponsor immediately.', 'Every effort will be made to maintain the anonymity and confidentiality of subjects participating', 'in this clinical study. However, because of the investigational nature of this treatment, the', 'Investigator agrees to allow representatives of the Sponsor, its designated agents, and authorized', 'employees of the appropriate regulatory agencies to inspect the facilities used in this study and to', 'have direct access to inspect, for purposes of verification, the hospital or clinical records of all', 'subjects enrolled in this study. A statement to this effect should be included in the ICF.', '13 DATA MANAGEMENT', \"Data will be entered into a clinical database as specified in the CRO's Data Management Plan.\", 'Quality control and data validation procedures will be applied to ensure the validity and accuracy', 'of the clinical database. Data will be reviewed and checked for omissions, apparent errors, and', 'values requiring further clarification using computerized and manual procedures. Data queries', 'requiring clarification will be communicated to the investigational site for resolution. Only', 'authorized personnel will make corrections to the clinical database, and all corrections will be', 'documented in an audit trail.', 'The coding of an AE, medical history and concomitant medication terms will be performed by', 'the CRO vendor and reviewed and approved by the Sponsor. Concomitant medications will be', 'coded using the World Health Organization Drug Dictionary (WHODrug) and AE/medical', 'history/surgery/non-drug therapy terms will be coded using the Medical Dictionary for', 'Regulatory Activities (MedDRA).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 108 of 117']\n\n###\n\n", "completion": "END"}